# Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

> **NCT02081118** · PHASE2 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 209 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** HM11260C
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02081118
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2015-03
- **Final completion:** 2015-04
- **Target enrollment:** 209 (ACTUAL)
- **Last updated:** 2016-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02081118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02081118, "Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02081118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*